MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Launched by PFIZER · Nov 28, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MagnetisMM-32 clinical trial is studying a new medicine called elranatamab for people with multiple myeloma (MM), a type of blood cancer that has returned after previous treatments. The trial aims to see how elranatamab works compared to standard combination therapies that include 2 to 3 other commonly used drugs. To participate, you need to be at least 18 years old, have a diagnosis of multiple myeloma, and have previously received treatment that did not work.
If you join the study, you will receive either elranatamab, given as a shot under the skin once a week, or a combination of other medications that may be taken at home or given at the clinic. The study team will closely monitor your health and progress during regular visits to the clinic and will follow up with you even after the treatment ends. This trial is important because it will help researchers understand how safe and effective elranatamab is compared to other treatments for multiple myeloma.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide.
- • Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria.
- • Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65).
- • Have clinical laboratory values within the specified range.
- • ECOG (Eastern Cooperative Oncology Group) performance status ≤2.
- • Not pregnant or breastfeeding and willing to use contraception.
- Exclusion Criteria:
- • Smoldering multiple myeloma.
- • Plasma cell leukemia.
- • Amyloidosis.
- • Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome.
- • Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement.
- • Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.
- • Any active, uncontrolled bacterial, fungal, or viral infection.
- • Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ)
- • Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy.
- • Unable to receive investigator's choice therapy.
- • Live attenuated vaccine within 4 weeks of the first dose of study intervention.
- • Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Edmonton, Alberta, Canada
Moncton, New Brunswick, Canada
Dallas, Texas, United States
Concord, New South Wales, Australia
Valhalla, New York, United States
Houston, Texas, United States
Murcia, , Spain
Clovis, California, United States
Cleveland, Ohio, United States
Providence, Rhode Island, United States
Newport Beach, California, United States
Quimper, , France
London, , United Kingdom
Montreal, Quebec, Canada
Cincinnati, Ohio, United States
Geelong, Victoria, Australia
Barcelona, , Spain
London, , United Kingdom
Bournemouth, Dorset, United Kingdom
Trondheim, , Norway
Freiburg, , Germany
Blacktown, New South Wales, Australia
Yamagata, , Japan
Taichung, , Taiwan
Poole, Dorset, United Kingdom
Eastbourne, East Sussex, United Kingdom
Oxford, Oxfordshire, United Kingdom
Stoke On Trent, Staffordshire, United Kingdom
Wolverhampton, , United Kingdom
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Le Mans, , France
Martin, , Slovakia
Madrid, , Spain
Toyohashi, Aichi, Japan
Greenville, North Carolina, United States
Bayonne, , France
Sugar Land, Texas, United States
Seoul, , Korea, Republic Of
Bunkyo Ku, Tokyo, Japan
Nagoya, Aichi, Japan
Okayama, , Japan
Sacramento, California, United States
Ulm, , Germany
Kobe, Hyogo, Japan
Jena, , Germany
Pescara, , Italy
Nürnberg, Bayern, Germany
Kyoto, , Japan
Brussels, , Belgium
örebro, , Sweden
Milano, , Italy
Beverly Hills, California, United States
Vannes, , France
Maidstone, Kent, United Kingdom
Charleroi, Hainaut, Belgium
Ogaki, Gifu, Japan
Speyer, , Germany
Madison, Wisconsin, United States
Ithaca, New York, United States
Madrid, , Spain
Fitzroy, Victoria, Australia
Pilar, Buenos Aires, Argentina
Maebashi, Gunma, Japan
Canterbury, , United Kingdom
Prague, , Czechia
Birtinya, Queensland, Australia
Tel Aviv, , Israel
Jena, Thüringen, Germany
Gent, Oost Vlaanderen, Belgium
Pisa, Toscana, Italy
Olomouc, , Czechia
Irving, Texas, United States
Zagreb, , Croatia
Zagreb, , Croatia
Madrid, , Spain
London, , United Kingdom
Porto Alegre, Rio Grande Do Sul, Brazil
London, London, City Of, United Kingdom
Jerusalem, Yerushalayim, Israel
Praha 2, , Czechia
Ioannina, , Greece
Kagoshima, , Japan
Athens, , Greece
Olomouc, Olomoucký Kraj, Czechia
Providence, Rhode Island, United States
Matsuyama, Ehime, Japan
Birmingham, England, United Kingdom
Maastricht, Limburg, Netherlands
Turku, Varsinais Suomi, Finland
La Plata, , Argentina
Okayama, , Japan
Lincoln, Nebraska, United States
Miami, Florida, United States
Koto, Tokyo, Japan
Firenze, Toscana, Italy
Mobile, Alabama, United States
València, , Spain
Temple, Texas, United States
Hornu, Hainaut, Belgium
La Roche Sur Yon, , France
Plantation, Florida, United States
Copenhagen, Hovedstaden, Denmark
Houston, Texas, United States
Plantation, Florida, United States
Seoul, Seoul Teukbyeolsi [Seoul], Korea, Republic Of
Salamanca, , Spain
Aarhus, Midtjylland, Denmark
São Paulo, , Brazil
Athens, , Greece
Tønsberg, Vestfold, Norway
Freiburg, Baden Württemberg, Germany
Pittsburgh, Pennsylvania, United States
Thessaloniki, Thessaloníki, Greece
Morgantown, West Virginia, United States
Gilly, Hainaut, Belgium
Indianapolis, Indiana, United States
Taichung, , Taiwan
Brno, Brno Město, Czechia
Aalborg, Nordjylland, Denmark
Tampere, Pirkanmaa, Finland
Trondheim, Sør Trøndelag, Norway
Oslo, , Norway
Greenville, South Carolina, United States
Terrassa, , Spain
Porto Alegre, Rio Grande Do Sul, Brazil
Irvine, California, United States
Ramat Gan, Hamerkaz, Israel
Brussels, Bruxelles Capitale, Région De, Belgium
Kofu Shi, Yamanashi, Japan
Oulu, Pohjois Pohjanmaa, Finland
Athens, Attikí, Greece
Athens, Attikí, Greece
Shibukawa, Gunma, Japan
Shiwa Gun Yahaba Cho, Iwate, Japan
örebro, , Sweden
Paris, , France
La Roche Sur Yon, Vendée, France
Barcelona, Catalunya [Cataluña], Spain
London, London, City Of, United Kingdom
London, , United Kingdom
Koto, Tokyo, Japan
Nagaizumi Cho, Shizuoka, Japan
Be'er Sheva, Hadarom, Israel
London, London, City Of, United Kingdom
Fort Collins, Colorado, United States
Ulm, Baden Württemberg, Germany
Helsinki, Uusimaa, Finland
Ioannina, ípeiros, Greece
Terrassa, Barcelona [Barcelona], Spain
Torino, Piemonte, Italy
Morristown, New Jersey, United States
Sacramento, California, United States
Verviers, , Belgium
Porto Alegre, Rio Grande Do Sul, Brazil
Sao Paulo, São Paulo, Brazil
Rio De Janeiro, , Brazil
Nice, Alpes Maritimes, France
Dordrecht, Zuid Holland, Netherlands
Falun, , Sweden
Pessac, Aquitaine, France
Badalona, Barcelona [Barcelona], Spain
London, London, City Of, United Kingdom
São Paulo, , Brazil
São Paulo, , Brazil
Dallas, Texas, United States
Nagaizumi Cho,Sunto Gun, Shizuoka, Japan
Lørenskog, Akershus, Norway
Kuopio, Pohjois Savo, Finland
Cincinnati, Ohio, United States
Greenville, North Carolina, United States
São Paulo, , Brazil
São Paulo, , Brazil
Palermo, Sicilia, Italy
Merriam, Kansas, United States
Tours, , France
Verviers, Liège, Belgium
Bologna, , Italy
Paris, , France
Yvoir, Namur, Belgium
Meldola, Emilia Romagna, Italy
Ancona, Marche, Italy
Vandoeuvre Lès Nancy, Lorraine, France
Hamm, , Germany
Porto Alegre, Rio Grande Do Sul, Brazil
Girona, Girona [Gerona], Spain
London, Sutton, United Kingdom
Nantes, Pays De La Loire, France
Créteil, Val De Marne, France
Petah Tikva, Hamerkaz, Israel
Fort Collins, Colorado, United States
Sp, São Paulo, Brazil
Hamburg, , Germany
Madrid, Madrid, Comunidad De, Spain
Tamarac, Florida, United States
Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina
Málaga, , Spain
São Paulo, , Brazil
São Paulo, , Brazil
Irvine, California, United States
València, Valenciana, Comunitat, Spain
Leawood, Kansas, United States
Mission, Kansas, United States
Prague, , Czechia
Cergy Pontoise, Val D'oise, France
Pontoise, Val D'oise, France
Berlin, , Germany
Salamanca, , Spain
Montreal, Quebec, Canada
Milano, Lombardia, Italy
Alexandroupolis, Anatolikí Makedonía Kai Thráki, Greece
Thessaloniki, Kentrikí Makedonía, Greece
Barcelona, Barcelona [Barcelona], Spain
Longmont, Colorado, United States
Tamarac, Florida, United States
Ciudad De Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Rio De Janeiro, , Brazil
Sao Paulo, , Brazil
Lincoln, Nebraska, United States
Lincoln, Nebraska, United States
Madison, Wisconsin, United States
Hawthorne, New York, United States
Ithaca, New York, United States
Dunkirk, Nord Pas De Calais, France
Murcia, Galicia [Galicia], Spain
Stuttgart, Baden Württemberg, Germany
Encino, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Cincinnati, Ohio, United States
Cottbus, , Germany
Braga, , Portugal
Madison, Wisconsin, United States
Legnano, Milano, Italy
Hornu, Hainaut, Belgium
Jau, , Brazil
Thessaloniki, , Greece
Badalona, , Spain
Brno, , Czechia
Girona, , Spain
Sp, , Brazil
Thessaloniki, , Greece
Boston, Massachusetts, United States
Ciudad De Buenos Aires, , Argentina
Stuttgart, , Germany
Alexandroupolis, , Greece
Barcelona, , Spain
Barakaldo, , Spain
València, , Spain
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported